» Articles » PMID: 38577028

Characteristics of Patients With Initial Infection (CDI) That Are Associated With Increased Risk of Multiple CDI Recurrences

Abstract

Background: Because interventions are available to prevent further recurrence in patients with recurrent infection (rCDI), we identified predictors of multiple rCDI (mrCDI) in adults at the time of presentation with initial CDI (iCDI).

Methods: iCDI was defined as a positive test in any clinical setting during January 2018-August 2019 in a person aged ≥18 years with no known prior positive test. rCDI was defined as a positive test ≥14 days from the previous positive test within 180 days after iCDI; mrCDI was defined as ≥2 rCDI. We performed multivariable logistic regression analysis.

Results: Of 18 829 patients with iCDI, 882 (4.7%) had mrCDI; 437 with mrCDI and 7484 without mrCDI had full chart reviews. A higher proportion of patients with mrCDI than without mrCDI were aged ≥65 years (57.2% vs 40.7%; < .0001) and had healthcare (59.1% vs 46.9%; < .0001) and antibiotic (77.3% vs 67.3%; < .0001) exposures in the 12 weeks preceding iCDI. In multivariable analysis, age ≥65 years (adjusted odds ratio [aOR], 1.91; 95% confidence interval [CI], 1.55-2.35), chronic hemodialysis (aOR, 2.28; 95% CI, 1.48-3.51), hospitalization (aOR, 1.64; 95% CI, 1.33-2.01), and nitrofurantoin use (aOR, 1.95; 95% CI, 1.18-3.23) in the 12 weeks preceding iCDI were associated with mrCDI.

Conclusions: Patients with iCDI who are older, on hemodialysis, or had recent hospitalization or nitrofurantoin use had increased risk of mrCDI and may benefit from early use of adjunctive therapy to prevent mrCDI. If confirmed, these findings could aid in clinical decision making and interventional study designs.

Citing Articles

Recurrent Infection and Outcome of Fecal Microbiota Transplantation Use: A Population-Based Assessment.

Mehta N, Goodenough D, Gupta N, Thomas S, Mehta C, Prakash R Open Forum Infect Dis. 2024; 11(7):ofae309.

PMID: 38975247 PMC: 11227225. DOI: 10.1093/ofid/ofae309.


Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.

Kraft C, Sims M, Silverman M, Louie T, Feuerstadt P, Huang E Infect Dis Ther. 2024; 13(10):2105-2121.

PMID: 38941068 PMC: 11416444. DOI: 10.1007/s40121-024-01007-z.

References
1.
Brown K, Langford B, Schwartz K, Diong C, Garber G, Daneman N . Antibiotic Prescribing Choices and Their Comparative C. Difficile Infection Risks: A Longitudinal Case-Cohort Study. Clin Infect Dis. 2020; 72(5):836-844. PMC: 7935390. DOI: 10.1093/cid/ciaa124. View

2.
Olsen M, Yan Y, Reske K, Zilberberg M, Dubberke E . Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect. 2015; 21(2):164-70. DOI: 10.1016/j.cmi.2014.08.017. View

3.
Brown K, Khanafer N, Daneman N, Fisman D . Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013; 57(5):2326-32. PMC: 3632900. DOI: 10.1128/AAC.02176-12. View

4.
Huttner A, Verhaegh E, Harbarth S, Muller A, Theuretzbacher U, Mouton J . Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015; 70(9):2456-64. DOI: 10.1093/jac/dkv147. View

5.
Ianiro G, Murri R, Sciume G, Impagnatiello M, Masucci L, Ford A . Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent Clostridioides difficile Infection Treated With Fecal Microbiota Transplantation or Antibiotics: A Prospective Cohort Study. Ann Intern Med. 2019; 171(10):695-702. DOI: 10.7326/M18-3635. View